Non-thionamide antithyroid drug options in Graves’ hyperthyroidism

References

• Robert Graves: EH. Graves’ disease of the thyroid. J Perioper Pract. 2012;22(5):176. Epub 2012/ 06/23.
   PubMedGoogle Scholar
• Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301–316. Epub 2018/ 03/24.
   PubMed Web of Science ®Google Scholar
• Carlé A, Pedersen IB, Knudsen N, et al. Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study. Eur J Endocrinol. 2011;164(5):801–809.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hegedus L. Graves’ Disease. N Engl J Med. 2016;375:1552–1565. Epub 2016/ 11/01. ;(16):. ().
   PubMed Web of Science ®Google Scholar
• Abraham-Nordling M, Törring O, Hamberger B, et al. Graves’ disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid. 2005;15(11):1279–1286.
   PubMed Web of Science ®Google Scholar
• Leso V, Vetrani I, De Cicco L, et al. The Impact of Thyroid Diseases on the Working Life of Patients: a Systematic Review. Int J Environ Res Public Health. 2020;17:4295. Epub 2020/ 06/21.
   PubMed Web of Science ®Google Scholar
• Okosieme OE, Khan I, Taylor PN. Preconception management of thyroid dysfunction. Clin Endocrinol (Oxf). 2018;89(3):269–279. Epub 2018/ 05/01.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Tanda ML. Clinical practice Graves’ ophthalmopathy. N Engl J Med. 2009;360(10):994–1001.
   PubMed Web of Science ®Google Scholar
• Okosieme OE, Taylor PN, Evans C, et al. Primary therapy of Graves’ disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol. 2019;7(4):278–287. Epub 2019/ 03/05.
   PubMed Web of Science ®Google Scholar
• Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343–1421. Epub 2016/ 08/16.
   PubMed Web of Science ®Google Scholar
• Burch HB, Cooper DS. Management of Graves Disease: a Review. Jama. 2015;314(23):2544–2554. Epub 2015/ 12/17.
   PubMed Web of Science ®Google Scholar
• Francis N, Francis T, Lazarus JH, et al. Current controversies in the management of Graves’ hyperthyroidism. Expert Rev Endocrinol Metab. 2020;15(3):159–169. Epub 2020/ 04/22.
   PubMed Web of Science ®Google Scholar
• Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905–917.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Miyauchi A, Miyawaki N, et al. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013;98(12):4776–4783. Epub 2013/ 09/24.
   PubMed Web of Science ®Google Scholar
• Yang J, Li LF, Xu Q, et al. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China. Thyroid. 2015;25(3):278–283. Epub 2014/ 11/11.
   PubMed Web of Science ®Google Scholar
• Andersen SL, Olsen J, Laurberg P. Antithyroid Drug Side Effects in the Population and in Pregnancy. J Clin Endocrinol Metab. 2016;101(4):1606–1614. Epub 2016/ 01/28.
   PubMed Web of Science ®Google Scholar
• Li H, Okuda J, Akamizu T, et al. A hyperthyroid patient with Graves’ disease who was strongly resistant to methimazole: investigation on possible mechanisms of the resistance. Endocr J. 1995;42(5):697–704. Epub 1995/ 10/01.
   PubMed Web of Science ®Google Scholar
• Angell TE, Lechner MG, Nguyen CT, et al. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab. 2015;100(2):451–459. Epub 2014/ 10/25.
   PubMed Web of Science ®Google Scholar
• Suwansaksri N, Preechasuk L, Kunavisarut T. Nonthionamide Drugs for the Treatment of Hyperthyroidism: from Present to Future. Int J Endocrinol. 2018;2018:5794054. Epub 2018/ 06/01. 10.1155/2018/5794054.
   PubMed Web of Science ®Google Scholar
• Cooper DS, Daniels GH, Ladenson PW, et al. Hyperthyroxinemia in patients treated with high-dose propranolol. Am J Med. 1982;73(6):867–871. Epub 1982/ 12/01.
   PubMed Web of Science ®Google Scholar
• Okosieme OE, Lazarus JH. Current trends in antithyroid drug treatment of Graves’ disease. Expert Opin Pharmacother. 2016;17(15):2005–2017. Epub 2016/ 09/13.
   PubMed Web of Science ®Google Scholar
• Cooper DS. Antithyroid drugs in the management of patients with Graves’ disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab. 2003;88(8):3474–3481. Epub 2003/ 08/14.
   PubMed Web of Science ®Google Scholar
• Saleem T, Sheikh A, Masood Q. Resistant thyrotoxicosis in a patient with graves disease: a case report. J Thyroid Res. 2011;2011:649084. Epub 2011/ 08/17. DOI:10.4061/2011/649084.
   PubMedGoogle Scholar
• Sebastián-Ochoa A, Quesada-Charneco M, Fernández-García D, et al. Dramatic response to cholestyramine in a patient with Graves’ disease resistant to conventional therapy. Thyroid. 2008;18(10):1115–1117. Epub 2008/ 09/26.
   PubMed Web of Science ®Google Scholar
• Mori Y, Hiromura M, Terasaki M, et al. Very rare case of Graves’ disease with resistance to methimazole: a case report and literature review. The Journal of international medical research. 2021;49:300060521996192. Epub 2021/ 03/09.
   Google Scholar
• Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves’ disease. Immunol Res. 2012;54(1–3):191–203. Epub 2012/ 03/22.
   PubMed Web of Science ®Google Scholar
• Shen P, Fillatreau S. Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol. 2015;15(7):441–451. Epub 2015/ 06/13.
   PubMed Web of Science ®Google Scholar
• Carvalho DP, Dupuy C. Thyroid hormone biosynthesis and release. Mol Cell Endocrinol. 2017;458:6–15. Epub 2017/ 02/06. DOI:10.1016/j.mce.2017.01.038.
   PubMed Web of Science ®Google Scholar
• van der Spek AH, Fliers E, Boelen A. The classic pathways of thyroid hormone metabolism. Mol Cell Endocrinol. 2017;458:29–38. Epub 2017/ 01/23. DOI:10.1016/j.mce.2017.01.025.
   PubMed Web of Science ®Google Scholar
• Sinha KN, Van Middlesworth L. Effect of bile on thyroxine absorption in the rat. Am J Physiol. 1971;220(2):253–256. Epub 1971/ 02/01.
   PubMedGoogle Scholar
• Hillier AP. Autoregulation of thyroxine secretion into bile. J Physiol. 1972;221(2):471–476. Epub 1972/ 03/01.
   PubMed Web of Science ®Google Scholar
• Kohrle J, Gartner R. Selenium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):353–356. Epub 2009/ 11/28.
   Web of Science ®Google Scholar
• Northcutt RC, Stiel JN, Hollifield JW, et al. The influence of cholestyramine on thyroxine absorption. Jama. 1969;208(10):1857–1861. Epub 1969/ 06/09.
   PubMed Web of Science ®Google Scholar
• Lane LC, Cheetham TD, Perros P, et al. New Therapeutic Horizons for Graves’ Hyperthyroidism. Endocr Rev. 2020;41(6):873–884.
   PubMed Web of Science ®Google Scholar
• Soldin OP, Braverman LE, Lamm SH. Perchlorate clinical pharmacology and human health: a review. Ther Drug Monit. 2001;23(4):316–331. Epub 2001/ 07/31.
   PubMed Web of Science ®Google Scholar
• Barzilai D, Sheinfeld M. Fatal complications following use of potassium perchlorate in thyrotoxicosis. Report of two cases and a review of the literature. Isr J Med Sci. 1966;2(4):453–456. Epub 1966/ 07/01.
   PubMedGoogle Scholar
• Martino E, Aghini-Lombardi F, Mariotti S, et al. Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest. 1986;9(3):201–207. Epub 1986/ 06/01.
   PubMed Web of Science ®Google Scholar
• Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):723–733.
   PubMed Web of Science ®Google Scholar
• Bagchi N, Brown TR, Mack RE. Studies on the mechanism of inhibition of thyroid function by lithium. Biochim Biophys Acta. 1978;542(1):163–169. Epub 1978/ 08/03.
   PubMedGoogle Scholar
• Takami H. Lithium in the preoperative preparation of Graves’ disease. Int Surg. 1994;79:89–90. Epub 1994/ 01/01.
   PubMed Web of Science ®Google Scholar
• Kessler L, Palla J, Baru JS, et al. Lithium as an adjunct to radioactive iodine for the treatment of hyperthyroidism: a systematic review and meta-analysis. Endocr Pract. 2014;20(7):737–745. Epub 2014/ 05/06.
   PubMed Web of Science ®Google Scholar
• Timmer RT, Sands JM. Lithium intoxication. J Am Soc Nephrol. 1999;10(3):666–674. Epub 1999/ 03/12.
   PubMed Web of Science ®Google Scholar
• Oruch R, Elderbi MA, Khattab HA, et al. Lithium: a review of pharmacology, clinical uses, and toxicity. Eur J Pharmacol. 2014;740:464–473. Epub 2014/ 07/06. DOI:10.1016/j.ejphar.2014.06.042.
   PubMed Web of Science ®Google Scholar
• British National Formulary (BNF). Lithium Carbonate 2022 [cited 2022 26 October]. Available from: https://bnf.nice.org.uk/drugs/lithium-carbonate/#monitoring-requirements.
   Google Scholar
• Marine D. Iodine in the Treatment of Disease of the Thyroid Gland. Trans Am Clin Climatol Assoc. 1925;41:38–52. Epub 1925/ 01/01
   Google Scholar
• Erbil Y, Ozluk Y, Giriş M, et al. Effect of Lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab. 2007;92(6):2182–2189. Epub 2007/ 03/29.
   PubMed Web of Science ®Google Scholar
• Wolff J, Chaikoff IL. The inhibitory action of iodide upon organic binding of iodine by the normal thyroid gland. J Biol Chem. 1948;172(2):855. Epub 1948/ 02/01.
   PubMed Web of Science ®Google Scholar
• Eng PH, Cardona GR, Fang SL, et al. Escape from the Acute Wolff-Chaikoff Effect Is Associated with a Decrease in Thyroid Sodium/Iodide Symporter Messenger Ribonucleic Acid and Protein 1. Endocrinology. 1999;140(8):3404–3410. Epub 1999/ 08/05.
   PubMed Web of Science ®Google Scholar
• Sterling JB, Heymann WR. Potassium iodide in dermatology: a 19th century drug for the 21st century-uses, pharmacology, adverse effects, and contraindications. J Am Acad Dermatol. 2000;43(4):691–697. Epub 2000/ 09/27
   PubMed Web of Science ®Google Scholar
• Uchida T, Goto H, Kasai T, et al. Therapeutic effectiveness of potassium iodine in drug-naive patients with Graves’ disease: a single-center experience. Endocrine. 2014;47(2):506–511. Epub 2014/ 02/05.
   PubMed Web of Science ®Google Scholar
• Okamura K, Sato K, Fujikawa M, et al. Remission after potassium iodide therapy in patients with Graves’ hyperthyroidism exhibiting thionamide-associated side effects. J Clin Endocrinol Metab. 2014;99(11):3995–4002. Epub 2014/ 08/22.
   PubMed Web of Science ®Google Scholar
• Okamura K, Sato K, Fujikawa M, et al. Iodide-sensitive Graves’ hyperthyroidism and the strategy for resistant or escaped patients during potassium iodide treatment. Endocr J. 2022;69(8):983–997. Epub 2022/ 03/25.
   PubMed Web of Science ®Google Scholar
• Williams DE, Chopra IJ, Orgiazzi J, et al. Acute effects of corticosteroids on thyroid activity in Graves’ disease. J Clin Endocrinol Metab. 1975;41(2):354–361. Epub 1975/ 08/01.
   PubMed Web of Science ®Google Scholar
• Baeza A, Aguayo J, Barria M, et al. Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf). 1991;35(5):439–442. Epub 1991/ 11/01.
   PubMed Web of Science ®Google Scholar
• Bogazzi F, Bartalena L, Cosci C, et al. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab. 2003;88(5):1999–2002. Epub 2003/ 05/03.
   PubMed Web of Science ®Google Scholar
• Satoh T, Isozaki O, Suzuki A, et al. 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society. First edition. Endocr J. 2016;63(12):1025–1064. Epub 2016/ 10/18
   PubMed Web of Science ®Google Scholar
• Buchman AL. Side Effects of Corticosteroid Therapy. J Clin Gastroenterol. 2001;33(4):289–294.
   PubMed Web of Science ®Google Scholar
• Roti E, Montermini M, Roti S, et al. The effect of diltiazem, a calcium channel-blocking drug, on cardiac rate and rhythm in hyperthyroid patients. Arch Intern Med. 1988;148(9):1919–1921. Epub 1988/ 09/01.
   PubMedGoogle Scholar
• Dalan R, Leow MK. Cardiovascular collapse associated with beta blockade in thyroid storm. Exp Clin Endocrinol Diabetes. 2007;115(6):392–396. Epub 2007/ 08/19.
   PubMed Web of Science ®Google Scholar
• Hashim SA, Vanitallie TB. CHOLESTYRAMINE RESIN THERAPY FOR HYPERCHOLESTEREMIA: CLINICAL AND METABOLIC STUDIES. Jama. 1965;192(4):289–293. Epub 1965/ 04/26.
   PubMed Web of Science ®Google Scholar
• Scaldaferri F, Pizzoferrato M, Ponziani FR, et al. Use and indications of cholestyramine and bile acid sequestrants. Intern Emerg Med. 2013;8(3):205–210. Epub 2011/ 07/09.
   PubMed Web of Science ®Google Scholar
• Lin D, Suwantarat N, Bornemann M. Cholestyramine for thyrotoxicosis? J Fam Pract. 2013;62(4):E1–2. Epub 2013/ 04/10.
   PubMed Web of Science ®Google Scholar
• Yang Y, Hwang S, Kim M, et al. Refractory Graves’ Disease Successfully Cured by Adjunctive Cholestyramine and Subsequent Total Thyroidectomy. Endocrinol Metab (Seoul). 2015;30(4):620–625. Epub 2015/ 09/24.
   PubMedGoogle Scholar
• Rummaan A, Maryam M, Ali A, et al. Resistant type 2 amiodarone-induced thyrotoxicosis responsive to cholestyramine as an adjunctive therapy. Clin Med (Lond). 2021;21(5):e529–e30. Epub 2021/ 09/12.
   PubMed Web of Science ®Google Scholar
• Mercado M, Mendoza-Zubieta V, Bautista-Osorio R. Espinoza-de los Monteros AL. Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. J Clin Endocrinol Metab. 1996;81(9):3191–3193. Epub 1996/ 09/01.
   PubMed Web of Science ®Google Scholar
• Tsai WC, Pei D, Wang TF, et al. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves’ hyperthyroidism. Clin Endocrinol (Oxf). 2005;62(5):521–524. Epub 2005/ 04/28.
   PubMed Web of Science ®Google Scholar
• Solomon BL, Wartofsky L, Burman KD. Adjunctive cholestyramine therapy for thyrotoxicosis. Clin Endocrinol (Oxf). 1993;38(1):39–43. Epub 1993/ 01/01.
   PubMed Web of Science ®Google Scholar
• Kaykhaei MA, Shams M, Sadegholvad A, et al. Low doses of cholestyramine in the treatment of hyperthyroidism. Endocrine. 2008;34(1–3):52–55. Epub 2008/ 10/24.
   PubMed Web of Science ®Google Scholar
• Mölgaard J, von Schenck H, Olsson AG. Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia. Eur J Clin Pharmacol. 1989;36(5):455–460. Epub 1989/ 01/01.
   PubMed Web of Science ®Google Scholar
• Harmon SM, Seifert CF. Levothyroxine-cholestyramine interaction reemphasized. Ann Intern Med. 1991;115(8):658–659. Epub 1991/ 10/15.
   PubMed Web of Science ®Google Scholar
• Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15(Suppl 1):S3. Epub 2013/ 04/10.
   PubMed Web of Science ®Google Scholar
• El Fassi D, Nielsen CH, Hasselbalch HC, et al. The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol. 2006;154(5):623–632. Epub 2006/ 04/29.
   PubMed Web of Science ®Google Scholar
• El Fassi D, Nielsen CH, Bonnema SJ, et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study. J Clin Endocrinol Metab. 2007;92(5):1769–1772.
   PubMed Web of Science ®Google Scholar
• Heemstra KA, Toes RE, Sepers J, et al. Rituximab in relapsing Graves’ disease, a phase II study. Eur J Endocrinol. 2008;159(5):609–615.
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007;156(1):33–40. Epub 2007/ 01/16.
   PubMed Web of Science ®Google Scholar
• Cheetham TD, Cole M, Abinun M, et al. Adjuvant Rituximab-Exploratory Trial in Young People With Graves Disease. J Clin Endocrinol Metab. 2022;107(3):743–754.
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Curro N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422–431. Epub 2014/ 12/17.
   PubMed Web of Science ®Google Scholar
• Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432–441. Epub 2014/ 10/25.
   PubMed Web of Science ®Google Scholar
• El Fassi D, Nielsen CH, Junker P, et al. Systemic adverse events following rituximab therapy in patients with Graves’ disease. J Endocrinol Invest. 2011;34(7):e163–7. Epub 2010/ 12/21.
   PubMed Web of Science ®Google Scholar
• Gea-Banacloche JC. Rituximab-associated infections. Seminars in hematology. 2010;47:187–198. Epub 2010/ 03/31.
   Google Scholar
• Berger JR, Malik V, Lacey S, et al. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neurovirol. 2018;24(3):323–331. Epub 2018/ 03/07.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496–1502. Epub 2012/ 11/09.
   PubMed Web of Science ®Google Scholar
• Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017;8(1):12. Epub 2017/ 11/17.
   PubMed Web of Science ®Google Scholar
• Casany-Fernandez R, Gascon-Gimenez F, Matarredona Solaz EJ, et al. Letter to the Editor: remission of Graves’ Disease After Initiation of Ocrelizumab in Patients with Multiple Sclerosis. Thyroid. 2022. Epub 2022/ 11/24. DOI: 10.1089/thy.2022.0398.
   PubMed Web of Science ®Google Scholar
• Ristov J, Espie P, Ulrich P, et al. Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody. Am J Transplant. 2018;18(12):2895–2904. Epub 2018/ 04/18.
   PubMed Web of Science ®Google Scholar
• Huber AK, Finkelman FD, Li CW, et al. Genetically driven target tissue overexpression of CD40: a novel mechanism in autoimmune disease. J Immunol. 2012;189(6):3043–3053. Epub 2012/ 08/14.
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Stan MN, Frommer L, et al. A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial. J Clin Endocrinol Metab. 2020;105(3):696–704. Epub 2019/09/13.
   Web of Science ®Google Scholar
• Smith B, Kiessling A, Lledo-Garcia R, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. mAbs. 2018;10(7):1111–1130. Epub 2018/ 08/22.
   PubMed Web of Science ®Google Scholar
• Howard JF Jr., Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661–e73. Epub 2019/ 05/24.
   PubMed Web of Science ®Google Scholar
• Zuercher AW, Spirig R, Baz Morelli A, et al. Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019;18(10):102366. Epub 2019/ 08/14.
   PubMed Web of Science ®Google Scholar
• Ulrichts P, Guglietta A, Dreier T, et al. Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372–4386. Epub 2018/ 07/25.
   PubMed Web of Science ®Google Scholar
• Barbesino G, Salvi M, Freitag SK. Future Projections in Thyroid Eye Disease. J Clin Endocrinol Metab. 2022;107(Supplement_1):S47–s56. Epub 2022/ 11/09.
   PubMedGoogle Scholar
• Neumann S, Eliseeva E, McCoy JG, Napolitano G, Giuliani C, Monaco F, Huang W, Gershengor n MC. A new small-molecule antagonist inhibits Graves’ disease antibody activation of the TSH receptor. J Clin Endocrinol Metab. 2011;96(2):548–554. Epub 2010/ 12/03.
   PubMed Web of Science ®Google Scholar
• Latif R, Realubit RB, Karan C, Mezei M, Davies TF. TSH Receptor Signaling Abrogation by a Novel Small Molecule. Front Endocrinol (Lausanne). 2016;7:130. Epub 2016/ 10/13. DOI: 10.3389/fendo.2016.00130
   PubMed Web of Science ®Google Scholar
• Evans M, Sanders J, Tagami T, et al. Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample. Clin Endocrinol (Oxf). 2010;73(3):404–412. Epub 2010/ 06/17.
   PubMed Web of Science ®Google Scholar
• Sanders J, Evans M, Betterle C, Sanders P, Bhardwaja A, Young S, Roberts E, Wilmot J, Richards T, Kiddie A, Small K, Platt H, Summerhayes S, Harris R, Reeve M, Coco G, Zanchetta R, Chen S, Furmaniak J, Smith BR. A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity. Thyroid. 2008;18(7):735–746. Epub 2008/ 07/18
   PubMed Web of Science ®Google Scholar
• Furmaniak J, Sanders J, Young S, et al. In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70). Auto Immun Highlights. 2012;3(1):19–25. Epub 2012/ 04/01.
   PubMedGoogle Scholar
• Furmaniak J, Sanders J, Sanders P, et al. TSH receptor specific monoclonal autoantibody K1-70 TM targeting of the TSH receptor in subjects with Graves‘ disease and Graves‘ orbitopathy—Results from a phase I clinical trial. Clin Endocrinol (Oxf). 2022;96(6):878–887. Epub 2022/ 01/29.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8:17. Epub 2015/ 05/30. DOI:10.1186/s40413-015-0063-2.
   PubMed Web of Science ®Google Scholar
• Pearce SHS, Dayan C, Wraith DC, et al. Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves’ Hyperthyroidism: a Phase I Study. Thyroid. 2019;29(7):1003–1011.
   PubMed Web of Science ®Google Scholar
• Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011;364(20):1920–1931. Epub 2011/ 05/20.
   PubMed Web of Science ®Google Scholar
• Vrca VB, Skreb F, Cepelak I, et al. Supplementation with antioxidants in the treatment of Graves’ disease; the effect on glutathione peroxidase activity and concentration of selenium. Clin Chim Acta. 2004;341(1–2):55–63. Epub 2004/ 02/18.
   PubMed Web of Science ®Google Scholar
• Calissendorff J, Mikulski E, Larsen EH, et al. Investigation of Graves’ Disease and Selenium: thyroid Hormones, Auto-Antibodies and Self-Rated Symptoms. Eur Thyroid J. 2015;4(2):93–98. Epub 2015/ 08/19.
   PubMedGoogle Scholar
• Leo M, Bartalena L, Rotondo Dottore G, et al. Effects of selenium on short-term control of hyperthyroidism due to Graves’ disease treated with methimazole: results of a randomized clinical trial. J Endocrinol Invest. 2017;40(3):281–287. Epub 2016/ 10/14.
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Riedl M, König J, et al. Placebo-controlled, randomized trial of selenium in graves hyperthyroidism. J Clin Endocrinol Metab. 2017;102(11):4333–4341. Epub 2017/ 11/02.
   PubMed Web of Science ®Google Scholar
• Zheng H, Wei J, Wang L, et al. Effects of selenium supplementation on graves’ disease: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2018;2018:3763565. Epub 2018/ 10/26. DOI:10.1155/2018/3763565.
   PubMed Web of Science ®Google Scholar
• Gallo D, Mortara L, Veronesi G, et al. Effect of selenium and vitamin D combined supplementation in early control of graves’ disease hyperthyroidism during methimazole treatment. Front Endocrinol (Lausanne). 2022;13:886451. Epub 2022/ 07/06. DOI:10.3389/fendo.2022.886451.
   PubMed Web of Science ®Google Scholar
• Watt T, Cramon P, Bjorner JB, Bonnema SJ, Feldt-Rasmussen U, Gluud C, Gram J, Hansen JL, Hegedus L, Knudsen N, Bach-Mortensen P, Nolsoe R, Nygaard B, Pociot F, Skoog M, Winkel P, Rasmussen AK. Selenium supplementation for patients with Graves’ hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. Trials. 2013;14(1):119. Epub 2013/ 06/21
   PubMedGoogle Scholar
• NICE. Thyroid Disease Guidelines: national Institute of Health and Care Excellence; 2019 [cited 2019 16 November]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ng10074/documents.
   Google Scholar
• Okosieme OE, Taylor PN, Dayan CM. Should radioiodine now be first line treatment for Graves’ disease? Thyroid Res. 2020;13(1):3. Epub 2020/ 03/14.
   PubMed Web of Science ®Google Scholar
• Eligar V, Taylor PN, Okosieme OE, et al. Thyroxine replacement: a clinical endocrinologist’s viewpoint. Ann Clin Biochem. 2016;53(4):421–433. Epub 2016/ 04/30.
   PubMed Web of Science ®Google Scholar
• Neumann S, Place RF, Krieger CC, et al. Future Prospects for the Treatment of Graves’ Hyperthyroidism and Eye Disease. Hormone Metab Res. 2015;47(10):789–796. Epub 2015/ 07/23.
   PubMed Web of Science ®Google Scholar